As part of its ambition for the United Kingdom to become a tech and science superpower by 2030, in 2023, the government announced a range of initiatives aimed at boosting investment and innovation in the life sciences sector. Innovators will have welcomed the R&D tax relief reforms whilst the Mansion House Compact (the largest UK pension providers committing 5% of their assets to unlisted equities by 2030) announced in July has provided some hope of alternative pools of capital to unlisted UK life sciences companies.
Whilst the impact of those initiatives remains to be seen (and of course with a general election looming) the UK life sciences industry is being positioned to play an integral part in the growth of the country’s economy with many recent legal and regulatory developments also seeking to enhance the attractiveness of the UK as a leading life sciences hub. The UK’s offer to prospective investors will be centred around access to innovation, the financial firepower of the City, the introduction of progressive and pragmatic regulation and a robust advisory ecosystem, which it hopes will allow it to differentiate itself from the EU.
Continue reading “Lead partner: The year the United Kingdom becomes a globally leading life sciences hub?”